Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797691 | 1.00 | HTR2A (0.39) | HTR2ADRD3DRD2TYRCA1 | |
| SCHEMBL6433600 | 1.00 | HTR2A (0.39) | HTR2ADRD3DRD2TYRCA1 | |
| SCHEMBL6433594 | 1.00 | HTR2A (0.39) | HTR2ADRD3DRD2TYRCA1 | |
| SCHEMBL5363218 | 0.84 | KDM4E (0.44) | ALDH1A1LMNA | |
| SCHEMBL5363211 | 0.84 | KDM4E (0.44) | ALDH1A1LMNA | |
| SCHEMBL6434090 | 0.83 | TSHR (0.34) | HTR2ADRD3DRD2TYRCA1 | |
| SCHEMBL5359940 | 0.81 | ALDH1A1 (0.55) | HTR2ADRD3DRD2ALDH1A1LMNA | |
| SCHEMBL5359944 | 0.81 | ALDH1A1 (0.55) | HTR2ADRD3DRD2ALDH1A1LMNA | |
| SCHEMBL5366806 | 0.81 | ALDH1A1 (0.55) | HTR2ADRD3DRD2ALDH1A1LMNA | |
| SCHEMBL5374721 | 0.81 | ALDH1A1 (0.48) | HTR2ADRD3DRD2TYRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | claimed |
| EP-1165495-B1 | RESORCINOL DERIVATIVES | PFIZER (US) | 2005-04-20 | — | — | EP | claimed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | claimed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | claimed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | claimed |
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050143594-A1 | Process for preparing resorcinol derivatives | BRADLEY STUART E (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1165495-B1 | RESORCINOL DERIVATIVES | PFIZER (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6861564-B2 | Process for preparing resorcinol derivatives | PFIZER INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20030088113-A1 | Process for preparing resorcinol derivatives | BRADLEY STUART EDWARD (GB) | 2003-05-08 | — | — | US | disclosed |
| US-6504037-B2 | Reacting a cyclohexanedione or chromene-one derivative with 1,8-diazabicyclo(5.4.0)undec-7ene | WARNER-LAMBERT COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020032352-A1 | Process for preparing resorcinol derivatives | PFIZER PRODUCTS INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143594-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | HTR2A 2963/4885DRD3 172/4885DRD2 192/4885 |
| US-20030088113-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | HTR2A 2963/4885DRD3 172/4885DRD2 192/4885 |
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | HTR2A 2770/4885DRD3 434/4885DRD2 398/4885 |
| US-20020032352-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | HTR2A 2963/4885DRD3 172/4885DRD2 192/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | HTR2A 2770/4885DRD3 434/4885DRD2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.